Dianthus Therapeutics, Inc. (DNTH) Soars 6.1%: Is Further Upside Left in the Stock?

Company Overview - Dianthus Therapeutics, Inc. (DNTH) shares increased by 6.1% to close at $17.86, supported by high trading volume, contrasting with a 15.3% loss over the past four weeks [1] - The company reported strong financial results for Q4 and full-year 2024, along with pipeline updates and business goals for 2025, which likely contributed to the recent share price increase [1] Financial Performance - The upcoming quarterly report is expected to show a loss of$ 0.86 per share, reflecting a year-over-year decline of 59.3%, while revenues are projected to be $1.15 million, an increase of 32.2% from the previous year [2] - The consensus EPS estimate for Dianthus has been revised 0.5% lower in the last 30 days, indicating a negative trend in earnings estimate revisions, which typically does not lead to price appreciation [3] Industry Context - Dianthus is part of the Zacks Medical - Biomedical and Genetics industry, where another company, Techne (TECH), saw a 1.8% increase in its stock price, closing at$ 58.38, but has returned -4.6% over the past month [3] - Techne's consensus EPS estimate for its upcoming report remains unchanged at $0.52, representing an 8.3% increase from the previous year [4]